RRAECs (Cat. No. RAEC, Sixin, Shanghai, China) were cultured in Dulbecco's modi ed Eagle medium (DMEM, Cat. No. C11995500CP, Gibco, Thermo Fisher Scienti c, Inc.) supplemented with 10% fetal bovine serum (FBS, Cat. No. 2123971P, Gibco, Thermo Fisher Scienti c, Inc.) and 1% penicillin and streptomycin (P/S, Cat. No.S110VJ, Shanghai Yuanpei Biotechnology Co., Ltd) at a temperature of 37 °C in a 5% CO2, water-saturated atmosphere. Once the cells reached a dense monolayer with a coverage rate of 75%-85%, they were digested using 0.25% trypsin-EDTA (Cat. No. ma0233, meilunbio) and routinely passaged every 2-3 days. Cells from the 2nd to 8th passage were utilized for subsequent experiments.
The endothelial cell injury model was established by subjecting RRAECs in logarithmic growth phase to Ang II (Cat. No. 10190038, Beijing Solarbio Science & Technology Co., Ltd) at a concentration of 5×10 -7 mol/L for a duration of 24 h. Prior to exposure to Ang II, the RRAECs were pretreated with Calycosin (3mg/L, Cat. No. SC8040, Beijing Solarbio Science & Technology Co., Ltd) and Tanshinone IIA (3mg/L, Cat. No. H31022558, Shanghai First Biochemical Pharmaceutical Co., Ltd) for 1 h, forming the drug group. The untreated RRAECs were used as a negative control [19] . The cells were serum-starved overnight before subsequent treatment. All samples were assayed in triplicate.